ABSTRACT
INTRODUCTION
Incretins are gut hormones that facilitate insulin secretion upon food ingestion in a glucose-dependent manner. The glucose-dependent insulinotropic peptide (GIP) and glucagon like peptide-1 (GLP-1) exert their 2 of 32 insulinotropic actions on the pancreas via G-protein coupled receptors expressed on islet beta cells [1, 2] . Incretins also contribute to the control of energy homeostasis by modulation of satiety and food intake, energy expenditure as well as by additional effects on metabolic organs such as the liver and adipose tissue [2] . Indeed, the last decade is characterized by fast-growing usage of incretin mimetics in the therapeutic armamentarium of type 2 diabetes mellitus (T2DM) and obesity [3, 4] . The compelling evidence for the high benefit/low risk profile of GLP-1R agonists may broaden the indications for their utilization in other metabolic diseases, such as cardiovascular diseases and non-alcoholic fatty liver disease (NAFLD). In addition, clinical trials investigating the metabolic effects of combination therapy with GIP analogues are also emerging with overall beneficial synergistic improvement in glycaemic control and body weight [5] [6] [7] . However, extending the usage of GLP-1R agonists and implementation of GIPR agonist-based therapies necessitate a better understanding of their mechanisms of action in the central nervous system (CNS), liver and other peripheral tissues. Receptors for GLP-1 and GIP are also found on different immune cell populations, thus suggesting in addition direct immunoregulatory roles for these metabolic hormones. In this review, we aim to provide an up-to-date view of the immunoregulatory properties of these incretin hormones and their potential impact on physiological metabolic actions. To this end, we first describe the recent advances in our comprehension of immune cell networks in adipose tissue and brain, and their concerted modulation of organ-specific metabolic pathways in health and disease. This is followed by a brief description of the key metabolic activities of GLP-1 and GIP.
Finally, we summarize accumulating evidence outlining direct antiinflammatory and protective roles for these incretin hormones in distinct immune cells. There is now reasonable data to suggest that incretin-based therapeutic agents have an anti-inflammatory effect in addition to their ability to regulate blood glucose, which may provide additional benefits in the treatment of T2DM.
Immune Circuits Controlling Metabolism and Energy Balance in Adipose Depots
White adipose tissue (WAT) specializes in storing excessive energy in the form of triglycerides (TG) and in liberating fatty acids at times of energy deficiency such as fasting [8] . White adipocytes also release a variety of adipokines and lipid metabolites that signal to other tissues, contributing to systemic energy and glucose homeostasis. These are highly plastic cells that adjust their storage and secretory functions to the nutritional state of the organism [8] . When energy intake exceeds energy expenditure, white adipocytes grow in number (hyperplasia) and in size (hypertrophy) to accommodate energy excess [9] . Visceral WAT is also known for its robust inflammatory response in states of nutrient excess, which contributes to insulin resistance [9] . In contrast to WAT, the major Immunometabolism. 2019;1:e190004. https://doi.org/10.20900/immunometab20190004
Immunometabolism 3 of 32 function of brown adipose tissue (BAT) is to dissipate stored chemical energy in the form of heat in response to cold challenge, activation of the sympathetic nervous system or high calorie intake. This is enabled by uncoupling fatty acid oxidation from ATP production via the uncoupling protein-1 (UCP1) [8] . While formerly thought to exist solely in hibernating animals, BAT participates in maintaining energy balance in humans as well, where excess nutrients are dissipated as heat. Brown-like adipocytes termed beige adipocytes were also characterized in human WAT, particularly in subcutaneous WAT (scWAT). These cells arise in response to chronic cold exposure, prolonged β-adrenergic stimulation or high caloric intake [8] . Generally, stress, exercise and cold exposure induce beiging, while pathological processes such as obesity and inflammation reduce it [8] . Of note, in animal models the representative visceral WAT is epidydimal WAT (epiWAT) and the scWAT is inguinal WAT (ingWAT). The WAT cellular ecosystem also harbors a unique blend of immune cells, which cooperate with adipocytes to regulate metabolic homeostasis [10] .
During obesity, acute self-limiting inflammation allows healthy expansion of adipose tissue, as it preserves tissue integrity and helps it to adapt to the metabolic needs derived from over-nutrition. However, following prolonged positive energy balance, this physiological response becomes sustained and turns pathogenic. Indeed, obesity is characterized by proinflammatory transition of WAT resident and infiltrating immune cells, which contribute to systemic insulin resistance [11] . With the purpose of better understanding the potential immunoregulatory activity of GLP-1 and GIP on fat depot immunity, we will first summarize the current appreciation of their immune cell networks and their support or impairment of metabolism and energy homeostasis.
Macrophages are myeloid immune cells that are strategically positioned in nearly all tissues, where they play essential roles in responses to infection and injury. In addition, each tissue-resident macrophage population exhibits a distinct phenotype linked to the functional specialization of that tissue [12] . In WAT, macrophages are the most abundant immune cells and can comprise up to 40% of all stromal vascular cells in obese adipose tissue [13] [19] [20] [21] [22] . Less is known about their role in homeostatic conditions. In fact, a recent study has shown that WAT cDCs are poised to suppress inflammation by activating the β-catenin and PPARγ pathways, which are also important regulatory mechanisms for fat expansion. Persistent over-nutrition however interferes with these pathways leading to a pro-inflammatory switch of WAT-cDCs [23] .
T cells also regulate obesity-induced adipose tissue inflammation.
Interferon−γ(IFNγ)-producing CD4 + Th1 cells are increased in obesity, while CD4 + Th2 T cells are decreased [24] . Their unique properties depend on PPARγ [25] and IL-33 [26, 27] . Obesity is accompanied by a striking drop of Tregs in WAT [25, 28] , which may license the pro-inflammatory switch of other immune cells.
The recent past has seen great progress in our comprehension of immune cell circuits controlling energy balance [29] . Studies in mice revealed critical neuron-macrophage interactions, both in the CNS and in peripheral tissues including WAT and BAT, which impinge on energy and metabolic homeostasis (reviewed in [30] ). With respect to peripheral neuron-macrophage crosstalk, three independent studies have outlined intimate functional associations between sympathetic neurons and CX3CR1 + macrophages within WAT [31, 32] or BAT [33] , which were termed sympathetic-neuron associated macrophages (SAMs). Sympathetic innervation of WAT and BAT and production of the catecholamine norepinephrine (NE) is necessary and sufficient for the initiation of lipolysis. In the obese mouse ingWAT, SAM-mediated uptake and degradation of NE seems to contribute to the attenuated NE-stimulated lipolysis characteristic of the obese state [32] . In addition, increased catecholamine catabolism machinery in WAT SAMs, governed by NLRP3-inflammasome, has been linked to lipolysis reduction associated with aging [31] . In BAT, CX3CR1 + macrophages play an important supportive role in local sympathetic innervation [33] . Jointly, these studies highlight the potential immune-metabolic consequences of macrophage-governed tuning of NE availability in adipose tissue. [46, 47] . Upon nutrient ingestion, POMC is cleaved to α-melanocyte stimulating hormone, which is released from the POMC axons and binds to melanocortin 3/4 receptors on downstream neurons, leading to inhibition of food intake and enhancement of energy expenditure [48] .
Diets rich in saturated fatty acids (SFA) produce inflammation, microgliosis, and neuronal stress in the MBH region. A growing body of evidence pinpoints microglia, the resident macrophages of the CNS, as the cell population that primarily responds to SFA and mediates the inflammatory process in the MBH, which consequently leads to altered neuronal function (e.g., impairment of anorexigenic effect) [30, 49] .
Remarkably, depleting microglia from the MBH of mice abolishes inflammation and neuronal stress induced by excess SFA consumption and the consequential blunted neuronal response to leptin, therefore reducing food intake [50] . NF-κB-dependent signaling in microglial cells stimulated by dietary excess appears to play a pivotal role in mediating obesity susceptibility via enhancement of food intake and weight gain [51] . Obesity-associated hypothalamic microglia inflammation is biphasic. Initially the resident microglia are affected; however, it is suggested that bone marrow (BM)-derived monocytes gradually replace MBH microglia as diet-induced obesity persists [51] . In this respect, highfat-diet (HFD) rapidly stimulates expression of the fractalkine chemokine (CX3CL1) in hypothalamic neurons of obese-prone mice. Inhibition of hypothalamic CX3CL1 reduces hypothalamic inflammation and recruitment of BM-derived monocytes that promote the obese phenotype [52] . Yet, the deleterious role of fractalkine in microglia activation during diet-induced obesity has been challenged by another study demonstrating that microglial activation via the CX3CL1-CX3CR1 pathway actually mediates resistance of female mice to an obesogenic diet [53] . While the potential mechanisms underlying hypothalamic microglial activation in HFD-induced obesity remains inconclusive, it is generally accepted that microglia activation plays a pivotal role in the development of hypothalamic inflammation in obesity. Therefore, there is an increased interest in developing pharmacological approaches aiming at dampening their inflammatory activity in the hypothalamus to improve metabolic abnormalities commonly associated with obesity. As described below, incretins that are common in the CNS milieu bear the potential to improve metabolic traits also by restraining microglia activation.
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GLP-1

GLP-1-metabolic functions
Production and signaling: GLP-1 was identified as part of the gene sequence coding for pro-glucagon, which is expressed in L cells in the small and large intestines [1, 54] . GLP-1 is produced postprandially by L-cells in the proximal gut. Yet, it is also released at basal levels even during fasting, possibly from colonic L-cells, which are exposed to non-absorbed nutrients, bile acids, and microbial metabolites [55, 56] .
More recent studies have revealed that L-cells express genes for several other gut peptide hormones in addition to pro-glucagon [57] . with the increased expression of the proconvertase enzymes, which can exert an insulinotropic effect on the remaining beta cells [58, 59] . GLP-1 is also produced in the CNS, predominantly in the brainstem, and it is transported to various sites in the brain where it can prompt metabolic, cardiovascular, and neuroprotective actions [1] . Circulating GLP-1 is rapidly degraded by dipeptidyl peptidase IV (DPP4), a serine protease that is widely expressed throughout the body, especially in endothelial cells [60] .
GLP-1 exerts its effects via the G-coupled protein receptor (GLP-1R),
which is present in pancreatic beta and alpha cells, brain, heart and immune cells [1] . The presence of the canonical GLP-1R in hepatocytes is controversial, as it was not detected in mouse hepatocytes, but was described in rat [61] and human hepatocytes [62] . Whether GLP-1R is present in white adipocytes is also a matter of dispute, and as such, many of the effects of GLP-1 on this tissue may be mediated via systemic effects.
Pancreatic effects: GLP-1 and GIP are together responsible for more than 70% of postprandial insulin secretion [63] . GLP-1 has additional uniquely beneficial effects on pancreatic beta-cells; it induces their proliferation and survival [64, 65] and attenuates endoplasmatic reticulum (ER) stress via PKA activation, thereby allowing insulin secretion from stressed beta cells [66] .
Regulation of food intake and body weight: Extensive evidence has
demonstrated that GLP-1R agonism results in profound weight loss [67] , and the GLP-1R agonist liraglutide has been approved for obesity treatment [68] . Though numerous mechanisms such as increased thermogenesis and reduced lipid storage in WAT may be involved, human data have clearly shown that reduction in food intake as a result of GLP-1 activity in the CNS accounts for the majority of the weight lost effect [69] . the relative contribution of each pathway [67] . CNS endogenous GLP-1 is considered to play a physiologic role in the long-term regulation of energy balance, while circulating GLP-1 serves as a short-term satiation sign [70] .
GLP-1R is
Different areas and neurons clusters in the CNS were examined as potential targets for CNS-and L-cell-derived GLP-1 anorexigenic effects.
Accordingly, endogenous glucagon coding gene (Gcg) and GLP-1R + neurons with anorexigenic effects upon stimulation have been identified in the brainstem [71, 72] . However, the physiologic relevance of this circuit is yet to be fully uncovered. Moreover, the anorexigenic effect of GLP-1 seems to be independent of VAN circuits [73] . Alternatively, studies employing either GLP-1R agonists or silencing of Glpr1 gene expression strongly support a role for both hypothalamic and hindbrain GLP-1R in the physiological control of food intake. The GLP-1R agonist liraglutide can directly activate anorectic POMC/CART neurons in rodents and thus indirectly inhibit orexigenic AgRP/NPY neurons in the ARC to reduce food intake [74] . However, neuronal circuits in the hypothalamus probably account only partially for the anorexigenic response of peripheral GLP-1R
agonism [75] , and the complete array of GLP-1 agonism response in the CNS is more intricate and demands further investigation. However, the opposite effects on thermogenesis and energy expenditure were observed when GLP-1 acted via VANs. Accordingly, specific deletion of GLP-1R in VANs resulted in increased BAT thermogenesis, increased ingWAT beiging and increased energy expenditure, particularly under a HFD regimen [77] . In addition, a population of VANs expressing GLP-1R is synaptically connected to BAT, allowing transmission of GLP-1 signals to BAT [77] . These attenuating effects of GLP-1 on BAT thermogenesis via the gut-to-BAT neuronal pathway suggests that rather than contributing to heat dissipation, postprandial nutrients are allocated to energy conservation, but under nutrient excess, these same mechanisms would lead to obesity. Another possibility is that GLP-1R agonism directly induces brown-like properties in WAT. Indeed, the GLP-1R agonist exendin 4 reduces adiposity by promoting lipolysis, fatty acid oxidation and mitochondrial biogenesis in epiWAT of HFD-fed mice and in vitro in 3T3L1
Regulation of energy expenditure:
adipocytes [78] . These effects are dependent on expression of sirtuin 1 (SIRT1), a key regulator of lipid metabolism [78] . Furthermore, liraglutide administration to mice fed with a high-fat-high-sucrose diet, significantly upregulates the expression of brown adipose-specific markers in perigonadal fat in association with upregulation of AMPK-SIRT1-PGC1α cell signaling [79] . Overall, while these studies attribute a pivotal role to GLP-1 in mediating energy expenditure, although the mechanistic pathways are still incompletely understood.
Immunometabolism. 2019;1:e190004. https://doi.org/10.20900/immunometab20190004 pathway [87] . In non-alcoholic steatohepatitis (NASH) patients, liraglutide improved hepatic insulin sensitivity, reduced hepatic de novo lipogenesis and decreased adipose tissue lipolysis [88] . In this study, in vitro treatment of human primary hepatocytes with exendin 4 also inhibited lipogenesis and lipid accumulation [88] . Another study in T2DM patients uncovered that exendin 4 treatment plus pioglitazone reduces hepatic triglyceride content, decreases circulating levels of liver enzymes, and increases adiponectin levels, without changes in body weight, therefore demonstrating that GLP-1R agonists can improve hepatic steatosis independent of weight loss [89] . Collectively, in addition to systemic metabolic effects, direct effects on the liver exerted by GLP-1R agonists may be involved in improvement of steatosis and steatohepatitis.
WAT effects: While the administration of GLP-1R agonists affects WAT, the expression of the canonical GLP-1R on adipocytes is not widely accepted, despite some data from primary human and primate adipocytes indicating the presence of GLP-1R mRNA and protein [90, 91] . Central administration of GLP-1 was shown to reduce WAT mass. In addition,
central, but not peripheral administration, reduced expression of lipogenic enzymes expression in WAT and their triglyceride content. These effects were shown to be mediated via sympathetic outflow [92] . Compatible with that, infusion of GLP-1 into abdominal subcutaneous fat has failed to increase lipolysis in healthy human volunteers [93] . Altogether, current data suggests that the action of GLP-1 on WAT is predominantly indirect and mediated through augmentation of sympathetic tune.
GLP-1-immunoregulatory functions
Our In addition, exendin 4 is capable of ameliorating ER stress response and apoptosis in insulin-resistant murine primary macrophages isolated from experimental atherosclerotic lesions [102] . It also potentiates phagocytosis in macrophages and their governed clearance of Listeria monocytogenes [103] . With respect to WAT, adenoviral-guided over-expression of GLP-1 significantly improved insulin sensitivity in diabetic ob/ob mice and this has been associated with its ability to reduce the frequency of ATMs and their governed production of inflammatory cytokines and chemokines [104] (Scheme 1A). In this study, GLP-1R agonist exendin 4 also attenuated LPS-induced inflammation in 3T3-L1 adipocytes [104] , though the expression of the canonical GLP-1R by adipocytes is controversial. While these results attribute anti-inflammatory effects to GLP-1 augmentation in WAT ATMs, it remains elusive whether this effect is direct. Concerning microglia, murine BV-2 microglial cells express the proglucagon gene and secrete GLP-1, processes that are both enhanced by cAMP. High levels of the SFA palmitate downregulate proglucagon expression in these cells [105] .
GLP-1R is also expressed by BV-2 microglia cells, and its activation
counteracts TNFα-induced apoptosis, reduces oxidative stress and induces production of neurotrophic factors and nerve growth factors [106] . In cultured microglia, GLP-1 seems to be produced in activated amoeboidtype microglia and can mediate their morphological transition from nonactivated ramified type to activated amoeboid type [107] . GLP-1R agonists also stimulate microglial expression and secretion of β-endorphin in the hippocampus and spinal cord to produce anti-nociceptive effects and neuroprotection [108, 109] . Recently, it has been shown in a mouse model suggesting that GLP-1 plays a role in their maintenance [116] . In further support of this, treatment of non-obese diabetic (NOD) mice (a model for type 1 diabetes) with DPP4 inhibitor, leading to sustained GLP-1 and GIP activities, significantly increases the levels of plasma transforming growth factor beta-1 (TGF-β1), an anti-inflammatory cytokine, and increases the fractions of thymic and pancreatic lymph node Tregs contributing to remission of diabetes [117] . Nevertheless, the direct effect of GLP-1 on the levels and function of WAT Tregs remains unexplored (Scheme 1A). With respect to mast cells, which play a deleterious role in obesity-induced insulin resistance [45] , liraglutide treatment inhibits their pathological accumulation in experimental models of pulmonary hypertension [118] and obesity-related glomerulopathy [119] . Lipoproteins trigger initially endothelial cell activation and subsequently an innate immune response, dominated by Ly6C hi monocytes and macrophages [120] [121] [122] . Macrophage foam cell formation, characterized by cholesterol ester accumulation, is the hallmark of early atherogenesis.
While both inflammatory macrophages and resolving macrophages can be found in atherosclerotic plaques [122, 123] , the immunoregulatory mechanisms that dictate macrophage-governed atheroprogression versus atheroregression are incompletely understood [124] . In murine models of It is currently appreciated that gut immune cells exert control over systemic metabolism and diet-related metabolic disease by mechanisms that are incompletely understood. In a very recent study, it has been shown that integrin β7 + small intestinal intraepithelial T lymphocytes (natural IELs) modulate enteroendocrine activity by acting as gatekeepers that limit the number of L cells and bioavailability of GLP-1 [127] .
Accordingly, integrin β7-knockout mice that lack natural IELs displayed heightened basal energy metabolism and improved glucose tolerance.
When fed a high-fat and high-sugar diet, these mice were resistant to obesity, hypercholesterolemia, hypertension, and diabetes. Moreover, β7-integrin blocking protected mice from developing atherosclerosis and led to improved glucose tolerance in a high-cholesterol diet model. by DPP4, which is expressed by multiple gut immune cells [129] . However, it has been shown that DPP4 + cells of BM-derived hematopoietic cell origin mediate the selective degradation of fasting GIP, but not GLP-1 [130] .
Further substantiating the immunometabolic crosstalk between GLP-1 and the immune system, GLP-1 secretion by intestinal L cells and pancreatic alpha cells is stimulated by inflammatory signals and cytokines, particularly IL-6, under physiological stressful conditions, such as exercise and endotoxemia [131] [132] [133] . This enables maintenance of normal glucose levels under the aforementioned conditions. IL-6 effect on GLP-1 secretion has also been demonstrated in obesity and T2DM [131] .
Given the overall anti-inflammatory activity of GLP-1, as mentioned above, inflammation-induced GLP-1 production may be also a feedback mechanism to tune down inflammatory processes.
GIP
GIP-metabolic functions
Production and signaling: GIP is a 42-amino acid peptide hormone produced by K-cells located primarily in the proximal small intestine [55] .
GIP release from duodenal K-cells begins upon their sensing of glucose, fat or proteins soon after meal initiation and continues as long as nutrients are released from the stomach [134] . Similarly to GLP-1, GIP is also produced in the CNS, and circulating GIP is also rapidly degraded by DPP4 [60] . GIP exerts its actions by binding to the GIP receptor (GIPR), a Gprotein coupled receptor, and its activation results in the stimulation of adenylyl cyclase and Ca 2+ -independent phospholipase A2, activation of protein kinase A (PKA) and PKB [1] .
Pancreatic effects: GIPR signaling activates insulin biosynthesis and secretion in pancreatic beta cells, promotes their proliferation and differentiation and inhibits their apoptosis [135] . GIP-governed insulin secretion is mediated through cAMP/PKA and cAMP/Epac2 pathways [136] .
In line with this, Gipr −/− mice display impaired oral, but normal intraperitoneal glucose tolerance [137] . While GLP-1 inhibits, GIP elicits glucagon secretion from alpha cells [134] . Some T2DM patients have been reported to be refractory to GIP-stimulated insulin secretion, though normalization of their hyperglycemia restored sensitivity to GIP-induced insulin secretion [138] . As the molecular basis of this GIPR resistance is incompletely understood, GLP-1 has become a parent compound of incretin-based glucose-lowering medications.
Regulation of food intake:
With respect to GIP effects in the CNS, there are no conclusive effects on food intake [97] . However, GIP stimulates neural progenitor cell proliferation in the hippocampus and has been demonstrated to have protective effects and improve cognitive function in several neurodegenerative diseases such as Alzheimer and Parkinson [139] .
Immunometabolism. 2019;1:e190004. https://doi.org/10.20900/immunometab20190004 [147] . We suggest that GIP-induced TG storage capacity in white adipocytes is a protective mechanism under nutrient excess, since WAT is the organ best suited for fat storage, unlike liver or muscle where TG storage causes insulin resistance. In addition, as described below, [D-Ala2]GIP also mediates significant anti-inflammatory effects in WAT (Scheme 1A), which may contribute as well to its-governed improved metabolic phenotype.
Bone effects: Previous studies demonstrated the existence of an entero-osseous axis and established a major role for incretins in the nutrient-dependent regulation of bone metabolism. GIPR is present in both bone forming osteoblasts and bone-resorbing osteoclasts, yet GIP is considered an anabolic hormone favoring bone formation [148, 149] . In cultured osteoblastic cell lines, GIP treatment induces proliferation, differentiation and mineralization and inhibits apoptosis [150, 151] .
Studies with two existing types of GIPR-deficient mice have shown dissimilar results. Mice with exon 4-5 deletion had decreased bone formation parameters, as determined by bone mineral density and content, trabecular bone volume and increased resorption parameters [152] . Mice with exon 1-6 deletion had reduced bone strength and cortical thickness, despite increased number of osteoblasts and increased bone resorption with higher numbers of osteoclasts, suggesting increased bone turnover [153] . Despite these differences, other studies further indicate that GIP favors bone formation over resorption. Accordingly, mice
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Moreover, in mice with Streptozotocin-induced type 1 diabetes mellitus,
[D-Ala2]GIP treatment was sufficient to significantly prevent deterioration in bone matrix-quality associated with this model [155] . In human patients, short-term treatment with GIP has no effects on bone resorption [156] . However, a loss-of function polymorphism in GIPR is associated with a strong increase in fracture risks in women [157] . Despite contradictory findings, GIPR agonists may prove useful in the treatment of osteoporosis and fragile bone syndrome associated with diabetes [156] .
GIP-immunoregulatory functions
As mentioned above, accumulating data reveals a controversy concerning the role of GIP in the control of body weight. Similar controversy surrounds the role of GIP in obesity-associated inflammatory responses. GIP administration in leptin-receptor deficient db/db mice increased ATM infiltration accompanied by higher levels of CCL2 and IL-6 mRNA expression [158] . Comparable results were also obtained by acute administration of GIP in healthy slightly obese volunteers [159] . In contrast, HFD-fed mice with enhanced genetic expression of GIP exhibited reduced ATM infiltration and pro-inflammatory cytokine expression and an ameliorated metabolic phenotype [160] . atherosclerotic plaque formation, macrophage infiltration and improved plaque stability [164] . In vitro, GIP treatment was sufficient to reduce MCP-1-induced monocyte migration as well as LPS-induced IL-6 secretion and MMP-9 activity in macrophage cell line. This was attributable to GIPdependent inhibition of NF-κB, JNK, ERK, and p38 in the endotoxin activated macrophages [164] . The gene encoding for GIPR (Gipr) has also been found in human circulating and gut cDC subsets [165] [166] [167] Therefore, there is great importance in determining the biological importance of GIPR in distinct immune cells, specifically in the context of metabolic inflammation and atherosclerosis. Such studies would be essential for understanding the safety of the emerging GIPR-based therapeutics (both agonists and antagonists) [3, 7, 173] .
While it is well-established that inflammation increases GLP-1 levels, how inflammatory stimuli mediate GIP secretion remains largely unknown. In one paper though, increased GIP secretion has been demonstrated in response to endotoxin, and this was driven by IL-1β [174] .
In contrast to the inducible effect of IL-6 on GLP-1 secretion [131, 132] , circulating GIP levels are significantly increased only in response to IL-1β,
but not IL-6 or TNFα administration [174] , suggesting that GLP-1 and GIP production is controlled by different inflammatory pathways.
Immunometabolism indeed, both GIPR agonism and GIPR antagonism either attenuate or augment inflammation [7] . As a result, pharmaceutical strategies enabling either activation [175, 176] or antagonism [177] of GIPR signaling are being simultaneously pursued for the treatment of diabetes and obesity.
Therefore, there is a great unmet need to dissect the exact repertoire of properties, such as serotonin [179, 180] and ghrelin [181] . Therefore, further studies are needed to explore the interplay between these hormones and their concerted immunometabolic functions. 
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